Cytological evaluation of biological prognostic markers from primary breast carcinomas

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Breast Cancer Research and Treatment

• Publication date

  1997-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1023/A:1005717924761PMID 9164679
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 8th annual San Antonio breast cancer symposium November 7–8, 1985

  2005cited by this paper
• Prognostic significance of p53 gene alterations in node-negative breast cancer

  2004cited by this paper
• Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project

  2004cited by this paper
• bcl-2 protein in invasive ductal breast carcinomas

  2004cited by this paper
• Analysis of estrogen and progesterone receptors on preoperative fine-needle aspirates

  2004influential reference
• Immunohistochemical versus biochemical estrogen-receptor and progesterone-receptor analysis: correlation with histological parameters

  2004cited by this paper
• Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma

  2004cited by this paper
• The p53 tumor suppressor gene in breast cancer

  2004cited by this paper
• Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas.

  1996cited by this paper
• Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.

  1995cited by this paper
• To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?

  1995cited by this paper
• Immunocytochemical determination of estrogen and progesterone receptors on 219 fine-needle aspirates of breast cancer. A prospective study.

  1995cited by this paper
• p53 status and the efficacy of cancer therapy in vivo.

  1994cited by this paper
• The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.

  1994cited by this paper
• Prognostic factors from the fine‐needle aspirate: Breast carcinoma nuclear grade

  1994cited by this paper
• Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen.

  1994cited by this paper
• Immunocytochemical assay of estrogen and progesterone receptors in fine needle aspirates from breast cancer patients.

  1994cited by this paper
• Prognostic value of cytological grading of fine-needle aspirates from breast carcinomas.

  1994cited by this paper
• Cell kinetics in human breast cancer: Comparison between the prognostic value of the cytofluorimetric S‐phase fraction and that of the antibodies to Ki‐67 and PCNA antigens detected by immunocytochemistry

  1994cited by this paper
• Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

  1994cited by this paper
• Mutant p53 protein associated with chemosensitivity in breast cancer specimens.

  1994cited by this paper
• Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

  1994cited by this paper
• Expression of bcl-2 gene confers multidrug resistance to chemotherapy- induced cell death

  1994cited by this paper
• Overexpression of p53 and prognosis in breast cancer

  1993cited by this paper
• The palpable breast nodule. A cost‐effectiveness analysis of alternate diagnostic approaches

  1993cited by this paper
• p53 as an independent prognostic marker in lymph node-negative breast cancer patients.

  1993cited by this paper
• Immunocytochemical determination of estrogen and progesterone receptors and flow cytometric DNA analysis of breast cancer on fine needle aspirates.

  1993cited by this paper
• The palpable breast nodule: A cost‐effectiveness analysis of alternate diagnostic approaches: The role of the needle aspiration biopsy

  1993cited by this paper
• The palpable breast nodule: a cost-effectiveness analysis of alternate diagnostic approaches. The role of the needle aspiration biopsy.

  1993cited by this paper
• Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

  1993cited by this paper
• Clinical and prognostic usefulness of immunohistochemical determination of Ki67 in breast cancer

  1993cited by this paper
• Comparison of Four Immunochemical Methods For the Measurement of Oestrogen Receptor Levels In Breast Cancer

  1992cited by this paper
• Treatment decisions in axillary node-negative breast cancer patients.

  1992cited by this paper
• Growth fraction (Ki-67 antibody) determination in early-stage breast carcinoma: histologic, clinical and prognostic correlations

  1992cited by this paper
• DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer.

  1992cited by this paper
• Tumour oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment

  1992cited by this paper
• Comparative features of carcinoma in situ and atypical ductal hyperplasia of the breast on fine-needle aspiration biopsy specimens.

  1991cited by this paper
• Ki‐67 immunostaining in human breast tumors and its relationship to prognosis

  1991cited by this paper
• Ki‐67 immunostaining in node‐negative stage I/II breast carcinoma. Significant correlation with prognosis

  1991cited by this paper
• Breast cancer prognostic factors: evaluation guidelines.

  1991cited by this paper
• Fine Needle Aspiration Cytodiagnosis As A Pre‐Requisite For Primary Medical Treatment of Breast Cancer

  1991cited by this paper
• Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors.

  1990cited by this paper
• Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance.

  1990cited by this paper
• Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry.

  1990cited by this paper
• Pathologic findings from the national surgical adjuvant breast and bowel projects (NSABP) prognostic discriminants for 8‐year survival for node‐negative invasive breast cancer patients

  1990cited by this paper
• Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.

  1990cited by this paper
• Immunocytochemical analysis of receptors for estrogen and progesterone in fine‐needle aspirates from human breast carcinomas

  1990cited by this paper
• How to use prognostic factors in axillary node-negative breast cancer patients.

  1990cited by this paper
• Evaluation of cell proliferation in breast carcinoma. Comparison of Ki‐67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count

  1990cited by this paper
• Adjuvant therapy for node-negative breast cancer.

  1989cited by this paper
• Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.

  1989cited by this paper
• Adjuvant therapy in node-negative breast cancer

  1989cited by this paper
• Influence of cancer histology on the success of fine needle aspiration of the breast.

  1989cited by this paper
• Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.

  1989cited by this paper
• Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma

  1989cited by this paper
• DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens

  1988cited by this paper
• Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.

  1988cited by this paper
• Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance.

  1988cited by this paper
• Fine Needle Aspiration of the Breast

  1988cited by this paper
• Immunocytochemical localization of estrogen receptor in human breast tissue.

  1988cited by this paper
• Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas.

  1988cited by this paper
• Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates.

  1987cited by this paper
• Estrogen receptor immunocytochemistry for preoperative determination of estrogen receptor status on fine-needle aspirates of breast cancer.

  1987cited by this paper
• Fine needle aspiration of the breast. Importance of the aspirator.

  1987cited by this paper
• Fine needle aspiration of the breast. Importance of the aspirator.

  1987cited by this paper
• Immunodetection of estrogen receptor and 52,000-dalton protein in fine needle aspirates of breast cancer tumors.

  1987cited by this paper
• Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.

  1986cited by this paper
• Monoclonal antiestrogen receptor antibody h 222 in fine needle aspiration cytologies of breast cancer a predictive marker of response to hormonal therapy

  1985cited by this paper
• The prognostic role of progesterone receptors in human breast cancer.

  1983cited by this paper
• Histochemical determination of estrogen and progesterone binding in fine needle aspirates of breast cancer. Correlation with conventional biochemical assays.

  1982cited by this paper
• Fine‐needle aspiration of the breast: Diagnoses and pitfalls. A review of 3545 cases

  1979cited by this paper

• Immunohistochemistry Applied to Breast Cytological Material

  2022cites this paper
• Breast cancer pathology services in sub-Saharan Africa: a survey within population-based cancer registries

  2020cites this paper
• Value of combined use of fine‐needle aspiration and core needle biopsy in palpable breast tumors performed by pathologist: Institut Curie experience

  2019cites this paper
• Cyclic Variation of Cellular Clock Proteins in the Mouse Estrous Ovary

  2016cites this paper
• Tocopherols inhibit oxidative and nitrosative stress in estrogen‐induced early mammary hyperplasia in ACI rats

  2015cites this paper
• A Quality Initiative of the Program in Evidence-Based Care ( PEBC ) , Cancer Care Ontario ( CCO ) Guideline on Hormone Receptor Testing in Breast Cancer

  2014cites this paper
• The prevalence of estrogen receptor-negative breast cancer in Ethiopia

  2014cites this paper
• The role of ThinPrep cytology in the investigation of ki-67 index, p53 and HER-2 detection in fine-needle aspirates of breast tumors.

  2013cites this paper
• Special Ancillary Techniques: Immunohistochemistry

  2013cites this paper
• Systematic Review on Hormone Receptor Testing in Breast Cancer

  2012cites this paper
• Steroid hormone receptors, MIB-1, p53, and c-erb-B2 expression on breast cancer: Comparison of immunohistochemistry on cell block and fine needle aspiration and tissue sample, in northwest Iran.

  2012cites this paper
• Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer.

  2012cites this paper
• Partial Inhibition of Estrogen-Induced Mammary Carcinogenesis in Rats by Tamoxifen: Balance between Oxidant Stress and Estrogen Responsiveness

  2011cites this paper
• Dietary quercetin exacerbates the development of estrogen-induced breast tumors in female ACI rats.

  2010influential citation
• Evaluation of apoptosis in cytologic specimens

  2010cites this paper
• Antioxidant butylated hydroxyanisole inhibits estrogen‐induced breast carcinogenesis in female ACI rats

  2009cites this paper
• Aurora kinases in solely estrogen-induced oncogenesis: Relation to centrosome amplification and chromosomal instability

  2008influential citation
• Estrogen-induced breast oncogenesis: modulation by an Aurora kinase inhibitor.

  2008cites this paper
• Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure.

  2008cites this paper
• Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays

  2007cites this paper
• The role of ThinPrep cytology in the evaluation of estrogen and progesterone receptor content of breast tumors.

  2006cites this paper
• Immunocytochemistry on Scrape Cytology in Breast Cancer

  2006cites this paper
• Immunocytochemistry on scrape cytology in breast cancer: will it unearth the weaker positives?

  2006cites this paper
• Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats.

  2006cites this paper
• Prognostication and treatment decision-making in early breast cancer

  2006cites this paper
• Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.

  2005cites this paper
• Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study

  2004cites this paper
• Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: Correlation with histologic sections determinations and diagnostic pitfalls

  2004cites this paper
• Prognostic implication of p53 protein expression in relation to nuclear pleomorphism and the MIB-1 counts in breast cancer

  2004cites this paper
• Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats

  2004cites this paper
• Proliferation rate, hormone receptor status and p53 expression in skeletal metastasis of breast carcinoma

  2004cites this paper
• Immunocytochemical evaluation of HER‐2/neu on fine‐needle aspirates from primary breast carcinomas

  2003cites this paper
• Functional relationship and gene ontology classification of breast cancer biomarkers.

  2003cites this paper
• Functional Relationship and Gene Ontology Classification of Breast Cancer Biomarkers

  2003cites this paper
• Global functional profiling of gene expression ? ? This work was funded in part by a Sun Microsystem

  2003cites this paper
• resumoO gene bcl-2 codifica uma proteína envolvida no processo de controle da apoptose.

  2003cites this paper
• Global functional profiling of gene expression.

  2003cites this paper
• Ki‐67 expression in breast carcinoma

  2003cites this paper
• Avaliação da expressão da proteína bcl-2 no carcinoma de mama: estudo em punção aspirativa por agulha fina; correlação com grau histológico em espécimes cirúrgicos correspondentes

  2003influential citation
• Measurement of proliferation marker Ki67 in breast tumour FNAs using laser scanning cytometry in comparison to conventional immunocytochemistry

  2003cites this paper
• Immunocytochemical evaluation of estrogen receptor on archival Papanicolaou‐stained fine‐needle aspirate smears

  2003cites this paper
• The prognostic value of hormone receptor detection by enzyme immunoassay and immunohistochemistry: a prospective study in patients with early breast cancer.

  2002cites this paper
• 29 - Immunohistochemistry of Needle Cytopunctures of Breast Carcinomas

  2002cites this paper
• The Prognostic Value of Hormone Receptor Detection by Enzyme Immunoassay and Immunohistochemistry: A Prospective Study in Patients with Early Breast Cancer

  2002cites this paper
• [Immunohistochemical determination of hormonal receptors on cell-blocks from fine-needle cytopunctures of breast carcinoma].

  2001cites this paper
• Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma.

  2001cites this paper
• Differential p53 protein expression in breast cancer fine needle aspirates: the potential for in vivo monitoring

  2001cites this paper
• Cytologic evaluation of cyclin D1 expression in primary breast carcinoma

  2001cites this paper
• Immunohistochemistry on Cell Blocks From Fine-Needle Cytopunctures of Primary Breast Carcinomas and Lymph Node Metastases

  2000cites this paper
• Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine‐needle aspirates and on surgical specimens of primary breast carcinomas

  2000cites this paper
• Primary systemic therapy in operable breast cancer.

  2000cites this paper
• P53 expression in patients with malignant and benign breast diseases.

  2000cites this paper
• Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.

  2000cites this paper
• Measurement of markers for breast cancer in a model system using laser scanning cytometry.

  2000cites this paper
• Predictors of response to chemotherapy.

  2000cites this paper
• Biological variables in non-small cell lung cancer: comparison between immunocytochemical determination on fine needle aspirates from surgical specimens and immunohistochemical determination on tissue sections.

  2000cites this paper
• Correlation of p53 Mutations in ThinPrep-Processed Fine Needle Breast Aspirates with Surgically Resected Breast Cancers

  2000cites this paper
• Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model.

  2000cites this paper
• Clinical studies of apoptosis and proliferation in breast cancer.

  1999cites this paper
• Bcl‐2 expression on fine‐needle aspirates from primary breast carcinoma

  1999cites this paper
• Monoclonal anti-androgen receptor antibodies: Production, characterization, and potential diagnostic applications

  1999cites this paper